MCE RedChemExpress

Leriglitazone-d₄

Cat. No.: HY-117727S

CAS No.: 1188263-49-1

Molecular Formula: C₁₉H₁₆D₄N₂O₄S


Molecular Weight: 376.46

Target: PPAR; Isotope-Labeled Compounds

Pathway: Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor; Others

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.



BIOLOGICAL ACTIVITY

Description Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone

(Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPAR γ agonist, stabilizes the PPAR γ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPAR γ C-terminal ligand-binding domain

(LBD) with Ki of 1.2 μ M \boxtimes induces transcriptional efficacy of the PPAR γ (LBD) with EC50 of 680 nM $^{[1]}$.

In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as

tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to

affect the pharmacokinetic and metabolic profiles of drugs^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Mosure SA,et al. Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARy Drug Pioglitazone. J Med Chem. 2019 Feb 28;62(4):2008-2023.

[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA